دورية أكاديمية
أعرض في EDS

Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines.

التفاصيل البيبلوغرافية
العنوان: Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines.
المؤلفون: Dong C; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Zhu W; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Wei L; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Kim JK; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Ma Y; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Kang SM; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA., Wang BZ; Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, 100 Piedmont Ave SE, Atlanta, GA, 30303, USA. bwang23@gsu.edu.
المصدر: Nature communications [Nat Commun] 2024 Jul 10; Vol. 15 (1), pp. 5800. Date of Electronic Publication: 2024 Jul 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Administration, Intranasal* , Cross Protection*/immunology , Influenza Vaccines*/immunology , Influenza Vaccines*/administration & dosage , Mice, Inbred BALB C* , Nanoparticles*/chemistry , Orthomyxoviridae Infections*/prevention & control , Orthomyxoviridae Infections*/immunology, Animals ; Female ; Humans ; Mice ; Antibodies, Viral/immunology ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Immunity, Mucosal/immunology ; Immunization/methods ; Lipids/chemistry ; Liposomes ; Nanovaccines/administration & dosage ; Nanovaccines/immunology ; RNA, Messenger/genetics ; RNA, Messenger/immunology ; Vaccination/methods
مستخلص: Enhancing influenza vaccine cross-protection is imperative to alleviate the significant public health burden of influenza. Heterologous sequential immunization may synergize diverse vaccine formulations and routes to improve vaccine potency and breadth. Here we investigate the effects of immunization strategies on the generation of cross-protective immune responses in female Balb/c mice, utilizing mRNA lipid nanoparticle (LNP) and protein-based PHC nanoparticle vaccines targeting influenza hemagglutinin. Our findings emphasize the crucial role of priming vaccination in shaping Th bias and immunodominance hierarchies. mRNA LNP prime favors Th1-leaning responses, while PHC prime elicits Th2-skewing responses. We demonstrate that cellular and mucosal immune responses are pivotal correlates of cross-protection against influenza. Notably, intranasal PHC immunization outperforms its intramuscular counterpart in inducing mucosal immunity and conferring cross-protection. Sequential mRNA LNP prime and intranasal PHC boost demonstrate optimal cross-protection against antigenically drifted and shifted influenza strains. Our study offers valuable insights into tailoring immunization strategies to optimize influenza vaccine effectiveness.
(© 2024. The Author(s).)
References: Sci Immunol. 2018 Jul 6;3(25):. (PMID: 29980618)
Emerg Microbes Infect. 2021 Dec;10(1):629-637. (PMID: 33691606)
PLoS One. 2010 Sep 01;5(9):. (PMID: 20824188)
Antiviral Res. 1987 Oct;8(3):151-60. (PMID: 3426185)
Sci Immunol. 2017 Jun 2;2(12):. (PMID: 28783656)
Nat Med. 2013 Dec;19(12):1597-608. (PMID: 24309663)
Front Immunol. 2019 Mar 18;10:440. (PMID: 30949165)
Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14. (PMID: 26056267)
Proc Natl Acad Sci U S A. 2021 May 11;118(19):. (PMID: 33941704)
J Leukoc Biol. 2014 Feb;95(2):215-24. (PMID: 24006506)
J Virol. 2012 Jun;86(12):6792-803. (PMID: 22491469)
Expert Rev Vaccines. 2012 May;11(5):595-607. (PMID: 22827245)
Curr Opin Virol. 2017 Feb;22:89-96. (PMID: 28088123)
iScience. 2021 Dec 17;24(12):103479. (PMID: 34841223)
J Vis Exp. 2015 Mar 19;(97):. (PMID: 25867050)
Cell Mol Immunol. 2021 Oct;18(10):2325-2333. (PMID: 34413488)
Science. 2022 Nov 25;378(6622):eabo2523. (PMID: 36302057)
Sci Immunol. 2022 Oct 28;7(76):eadd4853. (PMID: 35857583)
J Immunol. 2004 May 1;172(9):5553-60. (PMID: 15100298)
Immunol Rev. 2022 Aug;309(1):75-85. (PMID: 35815463)
Nat Immunol. 2022 Feb;23(2):186-193. (PMID: 35105982)
Nat Commun. 2021 Nov 26;12(1):6871. (PMID: 34836955)
Curr Opin Virol. 2020 Feb;40:28-36. (PMID: 32279026)
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5610-5. (PMID: 15044705)
Curr Opin Immunol. 2009 Jun;21(3):346-51. (PMID: 19500964)
Sci Immunol. 2022 Aug 12;7(74):eadd9947. (PMID: 35862488)
Viruses. 2022 Jul 30;14(8):. (PMID: 36016306)
Nature. 2006 Mar 23;440(7083):540-4. (PMID: 16525420)
J Infect Dis. 1999 Sep;180(3):579-85. (PMID: 10438342)
Mol Ther Nucleic Acids. 2022 Nov 09;30:421-437. (PMID: 36420215)
Nat Commun. 2018 Jan 24;9(1):359. (PMID: 29367723)
Nat Rev Immunol. 2020 Oct;20(10):615-632. (PMID: 32887954)
Nat Med. 2010 Dec;16(12):1389-91. (PMID: 21135852)
Lab Med. 2017 Feb;48(1):57-64. (PMID: 27760802)
Nat Rev Drug Discov. 2018 Apr;17(4):261-279. (PMID: 29326426)
Nat Rev Immunol. 2021 Feb;21(2):83-100. (PMID: 33353987)
J Immunol. 2019 Jan 15;202(2):374-381. (PMID: 30617119)
Vaccine. 2015 Jan 15;33(4):500-6. (PMID: 25498210)
ACS Appl Mater Interfaces. 2022 Feb 9;14(5):6331-6342. (PMID: 35084819)
Adv Nanobiomed Res. 2022 Mar;2(3):. (PMID: 35754779)
Curr Opin Virol. 2016 Feb;16:132-142. (PMID: 26974887)
Nat Rev Immunol. 2019 Jun;19(6):383-397. (PMID: 30837674)
Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. (PMID: 27702768)
Nat Rev Immunol. 2007 Feb;7(2):144-54. (PMID: 17259970)
Nanomedicine. 2023 Jan;47:102614. (PMID: 36265560)
Science. 2020 Feb 21;367(6480):852-853. (PMID: 32079760)
Annu Rev Immunol. 2016 May 20;34:575-608. (PMID: 27168245)
J Immunol. 2007 Feb 15;178(4):2370-9. (PMID: 17277143)
J Virol. 1998 Aug;72(8):6637-45. (PMID: 9658110)
Nat Rev Immunol. 2022 Apr;22(4):236-250. (PMID: 34312520)
Annu Rev Immunol. 2010;28:445-89. (PMID: 20192806)
J Immunol. 2015 Jul 1;195(1):203-9. (PMID: 26026054)
معلومات مُعتمدة: R01 AI101047 United States AI NIAID NIH HHS; R01 AI143844 United States AI NIAID NIH HHS; R01AI143844 U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID); R01AI101047 U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Hemagglutinin Glycoproteins, Influenza Virus)
0 (Influenza Vaccines)
0 (Lipid Nanoparticles)
0 (Lipids)
0 (Liposomes)
0 (Nanovaccines)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240801
رمز التحديث: 20240802
مُعرف محوري في PubMed: PMC11237032
DOI: 10.1038/s41467-024-50087-5
PMID: 38987276
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-50087-5